Cleveland Clinic researchers have made a groundbreaking discovery, uncovering a novel pathway implicated in cardiovascular disease associated with elevated levels of niacin, a common B vitamin traditionally used to lower cholesterol. Led by Dr. Stanley Hazen, the team identified 4PY, a metabolite produced from excess niacin, as a significant factor linked to heart disease. Their large-scale clinical studies revealed that higher levels of circulating 4PY were strongly correlated with increased risks of heart attack, stroke, and other adverse cardiac events. Preclinical investigations further demonstrated that 4PY directly initiates vascular inflammation, contributing to the damage of blood vessels and potentially leading to atherosclerosis over time.
Published in Nature Medicine, their study highlights the role of 4PY in vascular inflammation and explores genetic associations that underscore its contribution to cardiovascular health. These findings not only lay the groundwork for potential new therapeutic strategies to mitigate this inflammatory pathway but also bring hope for future treatments.
Dr. Hazen, Chair of Cardiovascular and Metabolic Sciences at Cleveland Clinic’s Lerner Research Institute, emphasises the significance of these discoveries: “What’s particularly compelling about our findings is the identification of a previously unknown yet substantial contributor to cardiovascular disease. Moreover, the measurable nature of this pathway opens avenues for diagnostic testing, setting the stage for novel interventions.”
Niacin, or vitamin B-3, is widely prevalent in Western diets and is fortified in staple foods to prevent nutritional deficiencies. Despite its benefits, concerns arise from the study’s observation that many individuals in their patient cohorts appear to have elevated 4PY levels due to excessive niacin intake. Dr. Hazen likens this to filling a bucket with multiple taps – once complete, overflow occurs, necessitating the body to process surplus niacin into metabolites like 4PY.
He stresses that the study does not advocate eliminating niacin intake but prompts a re-evaluation of its widespread fortification in foods. “Given these insights, there’s a valid discussion about the continued mandate for niacin fortification in staple foods,” says Dr. Hazen. He also cautions against the increasing popularity of over-the-counter niacin supplements, noting their potential risks and advising patients to consult healthcare providers before use. He recommends a balanced diet rich in fruits and vegetables and moderate carbohydrates.
Despite its initial promise, the findings also show why niacin has diminished as a primary cholesterol-lowering treatment. Once a cornerstone in cholesterol management, niacin’s effectiveness was overshadowed by newer medications and its association with adverse effects and higher mortality rates in previous studies. “Niacin’s historical efficacy in cholesterol reduction has been paradoxical,” explains Dr. Hazen. “Despite its ability to lower LDL (‘bad’) cholesterol, its clinical benefits fell short of expectations, possibly due to unclear adverse effects that counteracted its cholesterol-lowering benefits.”
Dr. Hazen underscores the importance of investigating residual cardiovascular risks, noting that their research contributes to understanding these complexities. He emphasises the need for long-term studies to assess how chronic elevation of 4PY levels may influence conditions like atherosclerosis and other related health outcomes, highlighting the potential impact of ongoing research on future health outcomes.
This study continues Dr. Hazen’s pioneering research into factors contributing to residual cardiovascular risk. His team’s longitudinal approach, involving the ongoing monitoring of patients and analysis of blood samples, aims to identify biochemical markers that predict cardiovascular disease development. Their work has been instrumental in uncovering links between gut microbial pathways, inflammatory processes, and metabolic diseases, advancing our understanding of these complex health issues.
More information: Marc Ferrell et al, A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk, Nature Medicine. DOI: 10.1038/s41591-023-02793-8
Journal information: Nature Medicine Provided by Cleveland Clinic
